hsa-mir-5193: Based on TCGA data, hsa-mir-5193 and hsa-miR-1343-3p showed weak and negative correlation with DUOX2 in pancreatic cancer (PC) [PMC7943273]. These microRNAs have also been found to be negatively associated with overall survival (OS) in PC patients [PMC7943273]. The putative binding sites of hsa-mir-5193 and hsa-miR-1343-3p in DUOX2 3′UTR have been identified [PMC7943273]. High expression of hsa-mir-5193 and hsa-miR-1343-3p has been associated with favorable OS in PC patients [PMC7943273]. Hsa-mir-5193 has been reported to inhibit the expression of TRIM11, leading to better OS in prostate cancer and suppression of HBV replication [PMC7943273]. Hsa-mir-5193 and hsa-miR-1343-3p have been verified to negatively correlate with DUOX2 through linear regression analysis [PMC7943273]. The miRNA targets shared between hsa_circ_0089761 and hsa_circ_0089761 include hsa-mir-5193, indicating their potential role in regulating gene expression [PMC9441041]. In a study comparing GLM vs. control groups, differential expression analysis revealed that hsa-mir-5193 was significantly upregulated [PMC9257833]. There are 43 co-targeting miRNAs, including hsa-mir-5193, which may have implications in cancer progression and development [PMC7607069].